Literature DB >> 15468601

Gene-directed enzyme prodrug therapy: a current assessment.

Stephanie R McKeown1, Claire Ward, Tracy Robson.   

Abstract

Gene-directed enzyme prodrug therapy involves tumor-specific delivery of a gene encoding a drug-metabolizing enzyme allowing metabolism of a non-toxic prodrug to a toxic species directly within tumor cells. This review covers the wide range of enzyme-prodrug combinations currently under preclinical and clinical investigation. Issues of tumor specificity and enhanced cytotoxicity through bystander effects will be discussed.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15468601

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  6 in total

Review 1.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  The cytotoxic activity of the phage E protein suppress the growth of murine B16 melanomas in vitro and in vivo.

Authors:  Raúl Ortiz; Jose Prados; Consolacion Melguizo; Ana R Rama; Ana Segura; Fernando Rodríguez-Serrano; Houria Boulaiz; Fidel Hita; Antonio Martinez-Amat; Roberto Madeddu; Juan L Ramos; Antonia Aranega
Journal:  J Mol Med (Berl)       Date:  2009-07-05       Impact factor: 4.599

3.  Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.

Authors:  C-S Chen; Y Jounaidi; T Su; D J Waxman
Journal:  Cancer Gene Ther       Date:  2007-09-14       Impact factor: 5.987

Review 4.  Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: evidence that they exert tumoricidal effects via tumor tropism (review).

Authors:  Bo-Rim Yi; Kelvin J Choi; Seung U Kim; Kyung-Chul Choi
Journal:  Int J Oncol       Date:  2012-06-20       Impact factor: 5.650

5.  Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+.

Authors:  Joshua C Doloff; Ting Su; David J Waxman
Journal:  BMC Cancer       Date:  2010-09-13       Impact factor: 4.430

6.  Mouse mammary tumor virus promoter-containing retroviral promoter conversion vectors for gene-directed enzyme prodrug therapy are functional in vitro and in vivo.

Authors:  Reinhard Klein; Bärbel Ruttkowski; Sonja Schwab; Thomas Peterbauer; Brian Salmons; Walter H Günzburg; Christine Hohenadl
Journal:  J Biomed Biotechnol       Date:  2008
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.